

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Follicular Lymphoma (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. In addition to CD3, which of the following does the novel drug glofitamab target?**

 - CD19
 - CD20**
 - CD70
- 2. At the recent ASH meeting, which of the following results were reported for the Phase II CITADEL-203 trial evaluating pascalisib in patients with relapsed/refractory (R/R) follicular lymphoma (FL)?**

 - The overall response rate was ~55% in all evaluable patients
 - 35% of all responding patients had their first response by 8 weeks
 - 95% of all evaluable patients had regression at target lesions**
- 3. Which of the following results was reported in the six-year follow-up of the Phase III RELEVANCE study of lenalidomide with rituximab versus R-chemotherapy (R-CHOP; rituximab, cyclophosphamide, vincristine and prednisone; rituximab and bendamustine) followed by rituximab maintenance for previously untreated FL?**

 - Lenalidomide with rituximab was associated with a greater benefit in overall survival
 - Overall and progression-free survival were similar with lenalidomide with rituximab and R-chemotherapy**
 - R-chemotherapy was associated with greater survival after progression
- 4. Which of the following PI3K inhibitors was associated with a high rate of serious adverse events in the Phase III CHRONOS-3 trial of relapsed indolent non-Hodgkin lymphoma?**

 - Copanlisib**
 - Umbralisib
 - Duvelisib
 - Idelalisib